News
CRMD
5.27
+1.54%
0.08
Weekly Report: what happened at CRMD last week (0415-0419)?
Weekly Report · 4d ago
CorMedix Shares Rise 6% After DefenCath Meets Payment Criteria
CorMedix shares were up 6% to $5.73. The company's DefenCath product meets criteria for a transitional drug add-on payment in the anti-infective functional category. The stock hit its 52-week high of $7 a share on April 12.
Dow Jones · 04/19 14:50
*CorMedix: DefenCath Catheter Lock Solution Is FDA Approved to Reduce Incidence of Catheter-Related Bloodstream Infections in Adult Patients With Kidney Failure >CRMD
Dow Jones · 04/19 12:35
*CorMedix: TDAPA Program Provides for Five Years Additional Payment Reimbursement >CRMD
Dow Jones · 04/19 12:34
*CorMedix DefenCath Meets Transitional Drug Add-On Payment Criteria >CRMD
Dow Jones · 04/19 12:33
*CorMedix: CMS Grants TDAPA to DefenCath >CRMD
Dow Jones · 04/19 12:32
CVAC, SBNY and CRMD are among after hour movers
Seeking Alpha · 04/17 21:01
CORMEDIX INC. ANNOUNCES U.S. INPATIENT COMMERCIAL AVAILABILITY OF DEFENCATH® (TAUROLIDINE AND HEPARIN)
Reuters · 04/15 12:30
Weekly Report: what happened at CRMD last week (0408-0412)?
Weekly Report · 04/15 10:46
12 Health Care Stocks Moving In Friday's After-Market Session
Qilian Intl Hldg Gr (NASDAQ:QLI) stock moved upwards by 50.4% to $1.14 during Friday's after-market session. Allarity Therapeutics stock rose 18.09% and Galecto stock increased by 5.58%. PaxMedica stock declined by 8.0% during the session.
Benzinga · 04/12 20:31
Wall Street Analysts Predict a 146.21% Upside in CorMedix (CRMD): Here's What You Should Know
NASDAQ · 04/11 13:55
CorMedix Price Target Maintained With a $19.00/Share by JMP Securities
Dow Jones · 04/09 12:50
JMP Securities Reiterates Market Outperform on Cormedix, Maintains $19 Price Target
Benzinga · 04/09 12:39
Truist Financial Remains a Buy on Cormedix (CRMD)
TipRanks · 04/09 11:35
Understanding Analyst Recommendation Reports: A Comprehensive Summary
TipRanks · 04/09 10:05
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Shandong Weigao Group Medical Polymer Co (OtherSHWGF) and Cormedix (CRMD)
TipRanks · 04/09 04:30
CorMedix enters into 5-year agreement with ARC Dialysis
Healthcare CorMedix enters into 5-year agreement with ARC Dialysis. CRMD expects to begin the commercialization of DefenCath in the inpatient setting on April 15th. The company has entered into a commercial supply contract with the Florida-based dialysis provider.
Seeking Alpha · 04/08 12:54
CorMedix Inc. Announces 5-Year Contract With Dialysis Provider, ARC Dialysis For The Supply Of DefenCath
CorMedix has entered into a 5-year commercial supply contract with Florida-based dialysis provider, ARC Dialysis, LLC for the supply of defenCath. DefenCath is the first-and-only FDA-approved antimicrobial catheter lock solution. The company expects to begin commercialization of the product in the inpatient setting in April.
Benzinga · 04/08 12:41
CORMEDIX INC: 5-YEAR COMMERCIAL SUPPLY CONTRACT WITH ARC DIALYSIS, LLC FOR SUPPLY OF DEFENCATH (TAUROLIDINE AND HEPARIN)
Reuters · 04/08 12:30
Weekly Report: what happened at CRMD last week (0401-0405)?
Weekly Report · 04/08 10:50
More
Webull provides a variety of real-time CRMD stock news. You can receive the latest news about Cormedix through multiple platforms. This information may help you make smarter investment decisions.
About CRMD
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.